Join Us at ESMO Breast 2021

We are showcasing MammaPrint^® and BluePrint^® genomic tests for comprehensive profiling of early-stage breast cancer.

Agendia’s activities at ESMO breast 2021:

Data Highlights – Oral Session

Title – 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature
Date – Saturday May 8th, 13:36-13:41
Speaker – A. Johansson (Stockholm, Sweden)

#IAMHERE

An intimate portrait series that illustrates the essence of 50 people who have been touched by breast cancer – Click here to view campaign.

Virtual Booth

Visit our virtual booth for more information and to speak with a member of our team.

See what Agendia’s assays can do for your patients:

Register for the meeting and visit our virtual booth

Click Here to Register Now

FOR PROVEN RESULTS

Trusted by leading physicians and institutions around the world

Our Tests

At the genomic level, physicians can examine the activity of specific genes inside a tumor – how they interact to drive the behavior of a tumor.

View More Information

Landmark Studies

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

View More Information